Soleno Therapeutics Dirección
Dirección controles de criterios 2/4
El CEO de Soleno Therapeutics es Anish Bhatnagar , nombrado en Jan 2017, tiene una permanencia de 7.83 años. compensación anual total es $4.12M, compuesta por 13.5% salario y 86.5% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.1% de las acciones de la empresa, por valor de $2.57M. La antigüedad media del equipo directivo y de la junta directiva es de 0.8 años y 5.4 años, respectivamente.
Información clave
Anish Bhatnagar
Chief Executive Officer (CEO)
US$4.1m
Compensación total
| Porcentaje del salario del CEO | 13.5% |
| Permanencia del CEO | 7.8yrs |
| Participación del CEO | 0.1% |
| Permanencia media de la dirección | less than a year |
| Promedio de permanencia en la Junta Directiva | 5.4yrs |
Actualizaciones recientes de la dirección
Recent updates
Companies Like Soleno Therapeutics (NASDAQ:SLNO) Can Afford To Invest In Growth
Nov 08
Soleno Therapeutics Nears FDA Decision: Strong Buy Targeting PWS Hyperphagia Treatments
Oct 10We're Not Worried About Soleno Therapeutics' (NASDAQ:SLNO) Cash Burn
Mar 08Here's Why We're Watching Soleno Therapeutics' (NASDAQ:SLNO) Cash Burn Situation
Sep 20Soleno sheds 13% as 1-for-15 reverse stock split takes effect
Aug 26Companies Like Soleno Therapeutics (NASDAQ:SLNO) Could Be Quite Risky
Aug 12Soleno Therapeutics surges 49% on regulatory pathway for Prader-Willi syndrome treatment
Jul 20Here's Why Soleno Therapeutics (NASDAQ:SLNO) Must Use Its Cash Wisely
May 10We're A Little Worried About Soleno Therapeutics' (NASDAQ:SLNO) Cash Burn Rate
Jan 24Soleno shares soar on FDA Orphan Drug status for Glycogen Storage Disease treatment
Jun 02Will Soleno Therapeutics (NASDAQ:SLNO) Spend Its Cash Wisely?
Mar 23Need To Know: Soleno Therapeutics, Inc. (NASDAQ:SLNO) Insiders Have Been Buying Shares
Jan 29
Soleno Therapeutics: Could Be Big Fish In The Small Pond
Jan 08Here's Why We're Not Too Worried About Soleno Therapeutics' (NASDAQ:SLNO) Cash Burn Situation
Dec 07Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$131m |
| Jun 30 2024 | n/a | n/a | -US$65m |
| Mar 31 2024 | n/a | n/a | -US$52m |
| Dec 31 2023 | US$4m | US$557k | -US$39m |
| Sep 30 2023 | n/a | n/a | -US$33m |
| Jun 30 2023 | n/a | n/a | -US$28m |
| Mar 31 2023 | n/a | n/a | -US$27m |
| Dec 31 2022 | US$1m | US$557k | -US$24m |
| Sep 30 2022 | n/a | n/a | -US$21m |
| Jun 30 2022 | n/a | n/a | -US$23m |
| Mar 31 2022 | n/a | n/a | -US$28m |
| Dec 31 2021 | US$4m | US$538k | -US$31m |
| Sep 30 2021 | n/a | n/a | -US$31m |
| Jun 30 2021 | n/a | n/a | -US$31m |
| Mar 31 2021 | n/a | n/a | -US$28m |
| Dec 31 2020 | US$3m | US$504k | -US$25m |
| Sep 30 2020 | n/a | n/a | -US$36m |
| Jun 30 2020 | n/a | n/a | -US$27m |
| Mar 31 2020 | n/a | n/a | -US$30m |
| Dec 31 2019 | US$822k | US$470k | -US$31m |
| Sep 30 2019 | n/a | n/a | -US$16m |
| Jun 30 2019 | n/a | n/a | -US$19m |
| Mar 31 2019 | n/a | n/a | -US$16m |
| Dec 31 2018 | US$952k | US$460k | -US$12m |
| Sep 30 2018 | n/a | n/a | -US$16m |
| Jun 30 2018 | n/a | n/a | -US$17m |
| Mar 31 2018 | n/a | n/a | -US$13m |
| Dec 31 2017 | US$1m | US$446k | -US$12m |
Compensación vs. Mercado: La compensación total de Anish($USD4.12M) está por debajo de la media de empresas de tamaño similar en el mercado US ($USD6.56M).
Compensación vs. Ingresos: La compensación de Anish ha aumentado mientras la empresa no es rentable.
CEO
Anish Bhatnagar (54 yo)
7.8yrs
Permanencia
US$4,116,434
Compensación
Dr. Anish Bhatnagar, M.D. has been Chief Executive Officer and Director of Soleno Therapeutics, Inc. since 2017 and serves as its President and Chief Operating Officer. Prior to Soleno, Dr. Bhatnagar serve...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| President | 7.8yrs | US$4.12m | 0.10% $ 2.6m | |
| Chief Financial Officer | 5yrs | US$1.21m | 0.070% $ 1.7m | |
| Senior Vice President of Regulatory Affairs | no data | US$1.03m | 0.091% $ 2.3m | |
| General Counsel | less than a year | sin datos | sin datos | |
| Vice President of People | less than a year | sin datos | sin datos | |
| Senior Vice President of Clinical Operations | no data | US$821.67k | 0.027% $ 676.9k | |
| Senior Vice President of Drug Development | 7.7yrs | sin datos | sin datos | |
| Chief Commercial Officer | less than a year | sin datos | sin datos | |
| Senior Vice President of Clinical Development | less than a year | sin datos | sin datos | |
| Chief Development Officer | less than a year | sin datos | sin datos | |
| Senior Vice President of Medical Affairs | less than a year | sin datos | sin datos |
0.8yrs
Permanencia media
55yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de SLNO no se considera experimentado ( 0.8 años antigüedad media), lo que sugiere un nuevo equipo.
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| President | 10.8yrs | US$4.12m | 0.10% $ 2.6m | |
| Member of Advisory Board | less than a year | sin datos | sin datos | |
| Independent Director | 10.4yrs | US$111.87k | 0.021% $ 514.2k | |
| Member of Advisory Board | no data | sin datos | sin datos | |
| Independent Director | 5.9yrs | US$51.87k | 0.015% $ 375.7k | |
| Member of Advisory Board | no data | sin datos | sin datos | |
| Member of Advisory Board | no data | sin datos | sin datos | |
| Independent Director | 5.4yrs | US$102.87k | 0.016% $ 407.1k | |
| Member of Advisory Board | no data | sin datos | sin datos | |
| Lead Independent Director | 1.3yrs | US$70.53k | 0% $ 0 | |
| Chair of the Development Advisory Board | less than a year | sin datos | sin datos | |
| Member of Advisory Board | no data | sin datos | sin datos |
5.4yrs
Permanencia media
62yo
Promedio de edad
Junta con experiencia: La junta directiva de SLNO se considera experimentada (5.4 años de antigüedad promedio).